Cryptococcus neoformans as a model for radioimmunotherapy of infections

Ekaterina Dadachova, Arturo Casadevall

Research output: Contribution to journalArticle

Abstract

There is an obvious and urgent need for novel approaches to treat infectious diseases. The use of monoclonal antibodies in therapy of infectious diseases is now experiencing renewed interest. During the last 5 years radioimmunotherapy (RIT), a modality previously developed only for cancer treatment, has been successfully adapted for the treatment of experimental fungal, bacterial, and viral infections. As our model organism for studying the efficacy, mechanisms, potential toxicity, and radioresistance to RIT, as well as for comparison of RIT with the existing antimicrobial therapies we have chosen the encapsulated yeast Cryptococcus neoformans (CN). The success of RIT approach in laboratory studies provides encouragement for feasibility of therapeutically targeting microbes with labeled antibodies. In addition, the creation of "panantibodies" for RIT which would recognize antigens shared by the whole class of pathogens such as fungi, for example, would facilitate the introduction of RIT into the clinic.

Original languageEnglish (US)
Article number830286
JournalInterdisciplinary Perspectives on Infectious Diseases
Volume2011
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Radioimmunotherapy
Cryptococcus neoformans
Infection
Communicable Diseases
Mycoses
Virus Diseases
Therapeutics
Bacterial Infections
Fungi
Yeasts
Monoclonal Antibodies
Antigens
Antibodies
Neoplasms

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Microbiology
  • Parasitology
  • Virology

Cite this

Cryptococcus neoformans as a model for radioimmunotherapy of infections. / Dadachova, Ekaterina; Casadevall, Arturo.

In: Interdisciplinary Perspectives on Infectious Diseases, Vol. 2011, 830286, 2011.

Research output: Contribution to journalArticle

@article{5d3170bbb3b84b969d9b68253fdea8ca,
title = "Cryptococcus neoformans as a model for radioimmunotherapy of infections",
abstract = "There is an obvious and urgent need for novel approaches to treat infectious diseases. The use of monoclonal antibodies in therapy of infectious diseases is now experiencing renewed interest. During the last 5 years radioimmunotherapy (RIT), a modality previously developed only for cancer treatment, has been successfully adapted for the treatment of experimental fungal, bacterial, and viral infections. As our model organism for studying the efficacy, mechanisms, potential toxicity, and radioresistance to RIT, as well as for comparison of RIT with the existing antimicrobial therapies we have chosen the encapsulated yeast Cryptococcus neoformans (CN). The success of RIT approach in laboratory studies provides encouragement for feasibility of therapeutically targeting microbes with labeled antibodies. In addition, the creation of {"}panantibodies{"} for RIT which would recognize antigens shared by the whole class of pathogens such as fungi, for example, would facilitate the introduction of RIT into the clinic.",
author = "Ekaterina Dadachova and Arturo Casadevall",
year = "2011",
doi = "10.1155/2011/830286",
language = "English (US)",
volume = "2011",
journal = "Interdisciplinary Perspectives on Infectious Diseases",
issn = "1687-708X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Cryptococcus neoformans as a model for radioimmunotherapy of infections

AU - Dadachova, Ekaterina

AU - Casadevall, Arturo

PY - 2011

Y1 - 2011

N2 - There is an obvious and urgent need for novel approaches to treat infectious diseases. The use of monoclonal antibodies in therapy of infectious diseases is now experiencing renewed interest. During the last 5 years radioimmunotherapy (RIT), a modality previously developed only for cancer treatment, has been successfully adapted for the treatment of experimental fungal, bacterial, and viral infections. As our model organism for studying the efficacy, mechanisms, potential toxicity, and radioresistance to RIT, as well as for comparison of RIT with the existing antimicrobial therapies we have chosen the encapsulated yeast Cryptococcus neoformans (CN). The success of RIT approach in laboratory studies provides encouragement for feasibility of therapeutically targeting microbes with labeled antibodies. In addition, the creation of "panantibodies" for RIT which would recognize antigens shared by the whole class of pathogens such as fungi, for example, would facilitate the introduction of RIT into the clinic.

AB - There is an obvious and urgent need for novel approaches to treat infectious diseases. The use of monoclonal antibodies in therapy of infectious diseases is now experiencing renewed interest. During the last 5 years radioimmunotherapy (RIT), a modality previously developed only for cancer treatment, has been successfully adapted for the treatment of experimental fungal, bacterial, and viral infections. As our model organism for studying the efficacy, mechanisms, potential toxicity, and radioresistance to RIT, as well as for comparison of RIT with the existing antimicrobial therapies we have chosen the encapsulated yeast Cryptococcus neoformans (CN). The success of RIT approach in laboratory studies provides encouragement for feasibility of therapeutically targeting microbes with labeled antibodies. In addition, the creation of "panantibodies" for RIT which would recognize antigens shared by the whole class of pathogens such as fungi, for example, would facilitate the introduction of RIT into the clinic.

UR - http://www.scopus.com/inward/record.url?scp=80052690283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052690283&partnerID=8YFLogxK

U2 - 10.1155/2011/830286

DO - 10.1155/2011/830286

M3 - Article

C2 - 21747848

AN - SCOPUS:80052690283

VL - 2011

JO - Interdisciplinary Perspectives on Infectious Diseases

JF - Interdisciplinary Perspectives on Infectious Diseases

SN - 1687-708X

M1 - 830286

ER -